252 related articles for article (PubMed ID: 33945995)
1. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
3. Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice.
Chen NG; Yu YA; Zhang Q; Szalay AA
J Transl Med; 2011 Sep; 9():164. PubMed ID: 21951588
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic vaccinia virus immunotherapy antagonizes image-guided radiotherapy in mouse mammary tumor models.
Umer BA; Noyce RS; Kieser Q; Favis NA; Shenouda MM; Rans KJ; Middleton J; Hitt MM; Evans DH
PLoS One; 2024; 19(3):e0298437. PubMed ID: 38498459
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
6. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
7. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
8. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
11. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy.
Frentzen A; Yu YA; Chen N; Zhang Q; Weibel S; Raab V; Szalay AA
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12915-20. PubMed ID: 19617539
[TBL] [Abstract][Full Text] [Related]
12. Deletion of
Potts KG; Irwin CR; Favis NA; Pink DB; Vincent KM; Lewis JD; Moore RB; Hitt MM; Evans DH
EMBO Mol Med; 2017 May; 9(5):638-654. PubMed ID: 28289079
[TBL] [Abstract][Full Text] [Related]
13. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer.
Umer BA; Noyce RS; Franczak BC; Shenouda MM; Kelly RG; Favis NA; Desaulniers M; Baldwin TA; Hitt MM; Evans DH
Cancer Immunol Res; 2020 May; 8(5):618-631. PubMed ID: 32127390
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
16. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
Patil SS; Gentschev I; Adelfinger M; Donat U; Hess M; Weibel S; Nolte I; Frentzen A; Szalay AA
PLoS One; 2012; 7(10):e47472. PubMed ID: 23091626
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68.
Ehrig K; Kilinc MO; Chen NG; Stritzker J; Buckel L; Zhang Q; Szalay AA
J Transl Med; 2013 Mar; 11():79. PubMed ID: 23531320
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
Guse K; Sloniecka M; Diaconu I; Ottolino-Perry K; Tang N; Ng C; Le Boeuf F; Bell JC; McCart JA; Ristimäki A; Pesonen S; Cerullo V; Hemminki A
J Virol; 2010 Jan; 84(2):856-66. PubMed ID: 19906926
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.
Adelfinger M; Bessler S; Frentzen A; Cecil A; Langbein-Laugwitz J; Gentschev I; Szalay AA
Viruses; 2015 Jul; 7(7):4075-92. PubMed ID: 26205404
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes.
Cho E; Islam SMBU; Jiang F; Park JE; Lee B; Kim ND; Hwang TH
Cancer Res Treat; 2020 Jan; 52(1):309-319. PubMed ID: 31401821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
